<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161940</url>
  </required_header>
  <id_info>
    <org_study_id>090-04</org_study_id>
    <nct_id>NCT01161940</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions</brief_title>
  <official_title>A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a bioequivalence study of nizatidine Capsules 300 mg of Dr.Reddy's Laboratories&#xD;
      Limited under fasting conditions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, balanced, randomized, two-treatment, two-period, two sequence, single dose,&#xD;
      crossover, comparative oral bioavailability study in healthy, adult, male human subjects&#xD;
      under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Nizatidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Axid 300 mg Capsules of Reliant Pharmaceuticals, US</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nizatidine</intervention_name>
    <description>Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited</description>
    <arm_group_label>Nizatidine</arm_group_label>
    <other_name>Axid 300 mg Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axid</intervention_name>
    <description>Axid 300 mg Capsules of Reliant Pharmaceuticals, US</description>
    <arm_group_label>Axid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males between 18 and 55 years of age (inclusive) living in and around&#xD;
             Ahmedabad city of western part of India.&#xD;
&#xD;
          -  Having a Body Mass Index (BMI) ≥ 18.0 kg/m2 (calculated as weight in kg/ height in&#xD;
             m2).&#xD;
&#xD;
          -  Have no significant diseases or clinically significant abnormal findings during&#xD;
             screening, medical history, physical examination, laboratory evaluations, ECG and&#xD;
             X-ray recordings.&#xD;
&#xD;
          -  Able to communicate effectively with study personnel. Able to give consent for&#xD;
             participation in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or idiosyncratic reaction to nizatidine or other related drugs.&#xD;
&#xD;
          -  Any disease or condition which might compromise the haemopoietic, renal, hepatic,&#xD;
             endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological,&#xD;
             gastrointestinal, or any other body system.&#xD;
&#xD;
          -  Ingestion of a medication at any time in 14 days before the start of the study. In any&#xD;
             such case subject selection will be at the discretion of the Principal&#xD;
             Investigator/Medical expert/co-investigator.&#xD;
&#xD;
          -  Any history or presence of asthma or nasal polyp.&#xD;
&#xD;
          -  A recent history of alcoholism (&lt;2years) or of moderate (180 ml/day) alcohol use.&#xD;
&#xD;
          -  Smokers, who smoke more than 10 cigarettes/day or those who cannot refrain from&#xD;
             smoking during study period.&#xD;
&#xD;
          -  The presence of clinically significant abnormal laboratory values during screening.&#xD;
&#xD;
          -  Use of any recreational drugs or history of drug addiction or testing positive in&#xD;
             pre-study drug scan.&#xD;
&#xD;
          -  History of psychiatric disorders.&#xD;
&#xD;
          -  A history of difficulty with donating blood.&#xD;
&#xD;
          -  Donations of blood (1 unit or 450 ml) within 90 days prior to receiving the first dose&#xD;
             of study medication. Note: Incase the blood loss is ≤ 200 L, subject may be dosed&#xD;
             after completion of 60 days of blood donation).&#xD;
&#xD;
          -  A positive hepatitis screen including hepatitis B surface antigen, anti-HCV and&#xD;
             anti-HAV antibodies.&#xD;
&#xD;
          -  A positive test result for HIV antibody and/or syphilis.&#xD;
&#xD;
          -  The receipt of an investigational product or participation in a drug research study&#xD;
             within a period of 90 days prior to the first dose of study medication (Elimination&#xD;
             half-life of the study drug should be taken into consideration for inclusion of the&#xD;
             subject in the study). (Note: If subject had participated in a study in which blood&#xD;
             loss is ≤200 mL, subject can be dosed after completion of 60 days of previous study).&#xD;
&#xD;
          -  An unusual diet, for whatever reason (eg., low-sodium), for four weeks prior to&#xD;
             receiving the study medication and throughout the subjects, participation in the&#xD;
             study. In any such case subject will be at the discretion of the Principal&#xD;
             Investigator/Medical expert/Co-investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charu Gautam, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Ltd.</affiliation>
  </overall_official>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <last_update_submitted>July 13, 2010</last_update_submitted>
  <last_update_submitted_qc>July 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>vice President, Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Nizatidine</keyword>
  <keyword>Crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nizatidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

